\n<\/p>\n
Around the world, public healthcare systems have struggled to reset post-pandemic, and in particular, the increasingly aged populations in Western countries are putting pressure on services, not least in the UK where \u2018NHS in crisis\u2019<\/a> is a regular headline in the media. As a result, private companies, many powered with technology, see a gap in the market. It\u2019s with this background that\u00a0Cera<\/a>, a proprietary software platform and in-home healthcare provider in the UK, has raised a $150 million in a mixture of debt and equity. The company said the majority of this is debt, but declined to give a split and also demured on its valuation.<\/p>\n The round was led by funds affiliated with BDT & MSD Partners and Schroders Capital in order to scale Cera\u2019s platform. The company says this is highly AI-driven, with proprietary modelling based on its own data, although it admits to using soma aspects of both Google\u2019s Gemini AI platform as well as Microsoft\u2019s version of ChatGPT.\u00a0<\/p>\n In 2022 Cera raised<\/a> $320 million (\u00a3260 million) in an equity and debt financing round, split roughly 50\/50.<\/p>\n According to CrunchBase it has 14 investors. Recognizable equity investors to date include Earlymarket, Guinness Ventures, DigitalHealth. London Accelerator, and long-time U.K. investor Robin Klein.\u00a0<\/p>\n A spokesperson for Cera added that although this has yet to be reflected in publicly-filed accounts, the company was EBITA-positive in 2023 and became free-cashflow positive in 2024, and is \u201cincreasingly a self-sustaining business,\u201d hence why it could raise this debt round. <\/p>\n In an interview with TechCrunch, Dr Ben Maruthappu MBE, Founder & CEO of Cera, said: \u201cWe are getting to profitability, plus we have very significant stale how we\u2019re using our technology and AI, and we\u2019ve expanded into more services in the home.\u201d<\/p>\n Cera carers use its app to plan their work and log patient symptoms. Using its AI modeling, Cera is then able to take that unstructured data (for example \u201cpatient had a fall in the night\u201d etc) and use it to predict the potential for patients to become subject to a greater risk of illness or injury. The company claims this has resulted in hospitalization reductions of up to 70%, a 20% reduction in patient falls, and hospital discharges that are up to five times faster, it said in a statement.\u00a0<\/p>\n The company has raised more than $407 million to date in a mix of equity and debt.<\/p>\n Competitors in the U.K. include Home Instead and Bluebird Care, which use non-proprietary apps to direct their staff. In the US, the closest comparisons to Cera include Signify Health and CVS Health, both of which were acquired by Nasdaq-listed CVS Health. Another is Honor, which has raised<\/a> $625 million to date.\u00a0<\/p>\n Maruthappu said: \u201cWe\u2019re taking pressure off the NHS and supporting it having more capacity to look after other patients. We\u2019ve also expanded into other service lines such as nursing services, physiotherapy, learning disabilities, physical disabilities, and providing mental health services in the home as well. So we\u2019re a much more comprehensive health care at home provider.\u201d<\/p>\n He also said the AI-driven aspect of the business was based on the data it collects: \u201cThe other key advantage is what we\u2019re doing with technology, more specifically AI\u2026 We\u2019re logging information about patients from those visits on our app that\u2019s given us now one of the largest home health care data sets in the world, definitely the largest in Europe, and we\u2019ve been able to analyze that data set in lots of different ways to build algorithms, algorithms that relate if Someone\u2019s going to have a fall before they do.\u201d<\/p>\n \u201cWe can predict over 80% of falls a week before they happen. That\u2019s statistically significant\u2026 So we actually reduce falls by over 20% because of our AI algorithm\u2026 We can also predict around 83% of hospitalizations again a week before they happen\u2026 reducing hospitalizations by up to 70%,\u201d he said. <\/p>\n In a statement, Rob Platek, partner and global head of credit at BDT & MSD, said: \u201cCera has achieved strong growth through a demonstrated ability to leverage technology to deliver exceptional care. We believe Cera is well positioned to further scale its business.\u201d<\/p>\n Cera says it is the U.K.\u2019s largest non-NHS healthcare provider, covering about covering about 30 million people with 10,000 carers and nurses and working with with over 150 local governments and two-thirds of NHS Integrated Care Systems.<\/p>\n It also claims an independent analysis conducted by U.K. consultancy Faculty found Cera\u2019s AI-led home healthcare model saves the U.K. healthcare system \u00a31 million a day.\u00a0<\/p>\n Cera is obviously keen to avoid the tarnish of healthcare startups such as Babylon Health, admittedly a very different business, which went bankrupt<\/a> and was sold for parts after attempting to do healthcare via a mere chatbot. <\/p>\n<\/div>\n